caa a22 4500 44581019X CHVBK 20180317145209.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s00415-010-5844-5 doi (NATIONALLICENCE)springer-10.1007/s00415-010-5844-5 One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients [Elektronische Daten] [Simona Malucchi, Francesca Gilli, Marzia Caldano, Arianna Sala, Marco Capobianco, Alessia di Sapio, Letizia Granieri, Antonio Bertolotto] MxA is an antiviral protein induced by type I interferons (IFN) and some viruses; MxA gene expression is an appropriate marker for measuring biologic activity of exogenous IFNβ, as its induction indicates IFNAR receptor stimulation. A recent study has shown that measurement of MxA mRNA, after 1year of treatment, predicts clinical responsiveness to IFNβ therapy. Loss of IFNβ bioactivity is mostly due to anti-IFNβ antibodies (both neutralizing and binding), non-compliance and receptor saturation. The aim of this study was to evaluate all possible causes of loss of IFNβ bioactivity after 1 year in treated patients. One hundred sixty-seven multiple sclerosis (MS) patients were included. One year after beginning IFNβ therapy, each patient underwent a blood test; MxA gene expression was measured by real time PCR, antiviral CPE assay to detect neutralizing antibodies (NAbs), and capture-ELISA (cELISA) to measure binding antibodies (BAbs). For MxA an upper normal threshold of 87 (RE) was considered, 20TRU/mL was the threshold for NAbs, and 1U for BAbs positivity. Thirty-seven out of 167 patients (22%) were MxA-negative; of these, 22 were both BAbs and NAbs+, whereas 12 were BAbs+ but Nabs−, and three were both BAbs and NAbs−. The following conclusions were drawn from the study: (1) MxA mRNA should be measured after 1year of IFNβ therapy; (2) after 1 year of IFNβ treatment, absence of IFNβ bioactivity was detected in 22% of the patients; (3) different biological phenomena and reduced compliance explain this absence; (4) identification of the reason for absence of IFN bioactivity improves patients' management. Springer-Verlag, 2010 Multiple sclerosis nationallicence Interferon beta nationallicence MxA nationallicence Neutralizing antibodies (NAbs) nationallicence Binding antibodies (BAbs) nationallicence Malucchi Simona Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut Gilli Francesca Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut Caldano Marzia Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut Sala Arianna Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut Capobianco Marco Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut di Sapio Alessia Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut Granieri Letizia Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut Bertolotto Antonio Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut Journal of Neurology Springer-Verlag 258/5(2011-05-01), 895-903 0340-5354 258:5<895 2011 258 415 https://doi.org/10.1007/s00415-010-5844-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-010-5844-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Malucchi Simona Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut NATIONALLICENCE 700 1- Gilli Francesca Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut NATIONALLICENCE 700 1- Caldano Marzia Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut NATIONALLICENCE 700 1- Sala Arianna Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut NATIONALLICENCE 700 1- Capobianco Marco Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut NATIONALLICENCE 700 1- di Sapio Alessia Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut NATIONALLICENCE 700 1- Granieri Letizia Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut NATIONALLICENCE 700 1- Bertolotto Antonio Neurologia 2, Centro Riferimento Regionale Sclerosi Multipla (CRESM), ASO S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano (Torino), Italy aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/5(2011-05-01), 895-903 0340-5354 258:5<895 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer